APA (7th ed.) Citation

S, P., SM, L., KC, P., MS, B., D, C., & HS, L. (2025). Population Pharmacokinetic and Pharmacodynamic Modeling Analysis of rhIL-7-hyFc, a Hybrid Fc-Fused Long-Acting Interleukin-7, to Support Optimal Dosing Regimens in Patients with Solid Cancer. Drug design, development and therapy, 19, 9303. https://doi.org/10.2147/DDDT.S564085

Chicago Style (17th ed.) Citation

S, Park, Lee SM, Pak KC, Byun MS, Choi D, and Lim HS. "Population Pharmacokinetic and Pharmacodynamic Modeling Analysis of RhIL-7-hyFc, a Hybrid Fc-Fused Long-Acting Interleukin-7, to Support Optimal Dosing Regimens in Patients with Solid Cancer." Drug Design, Development and Therapy 19 (2025): 9303. https://doi.org/10.2147/DDDT.S564085.

MLA (9th ed.) Citation

S, Park, et al. "Population Pharmacokinetic and Pharmacodynamic Modeling Analysis of RhIL-7-hyFc, a Hybrid Fc-Fused Long-Acting Interleukin-7, to Support Optimal Dosing Regimens in Patients with Solid Cancer." Drug Design, Development and Therapy, vol. 19, 2025, p. 9303, https://doi.org/10.2147/DDDT.S564085.